{
  "Trajectory16": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, what did the study find about the late cell-cycle genes (metagene 38) and their association with CT imaging features?",
      "ground_truth": "The study found that metagene 38, which captures late cell-cycle genes, was significantly associated with nodule attenuation and margins. When this metagene was active, lesions tended to be solid. When inactive, lesions tended to have poorly defined margins."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the survival duration for patients with different ground-glass opacity percentages?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, AVG(Survival_Duration) as avg_survival, COUNT(*) as patient_count FROM clinical_genomic GROUP BY Percent_GG ORDER BY Percent_GG;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Survival_Duration: FLOAT - Percent_GG: VARCHAR(20)",
        "ground_truth_query_result": "[{'Percent_GG': '0%', 'avg_survival': 2.8, 'patient_count': 89}, {'Percent_GG': '1-25%', 'avg_survival': 3.2, 'patient_count': 12}, {'Percent_GG': '25-50%', 'avg_survival': 3.6, 'patient_count': 6}, {'Percent_GG': '50-75%', 'avg_survival': 4.1, 'patient_count': 4}, {'Percent_GG': '75-<100%', 'avg_survival': 4.3, 'patient_count': 1}, {'Percent_GG': '100%', 'avg_survival': 4.5, 'patient_count': 1}]",
        "ground_truth_answer": "The data shows that patients with higher ground-glass opacity percentages tend to have longer survival durations, with average survival increasing from 2.8 years for solid tumors to 4.5 years for pure ground-glass opacity tumors."
      }
    },
    {
      "question_id": 2,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what percentage of patients with predominantly solid tumors (0-25% ground-glass) received chemotherapy compared to those with predominantly ground-glass tumors (>50%)?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT CASE WHEN Percent_GG IN ('0%', '1-25%') THEN 'Solid' WHEN Percent_GG IN ('50-75%', '75-<100%', '100%') THEN 'Ground-glass' END as tumor_type, COUNT(*) as total_patients, SUM(CASE WHEN Chemotherapy = 'Yes' THEN 1 ELSE 0 END) * 100.0 / COUNT(*) as chemo_percentage FROM clinical_genomic WHERE Percent_GG IN ('0%', '1-25%', '50-75%', '75-<100%', '100%') GROUP BY CASE WHEN Percent_GG IN ('0%', '1-25%') THEN 'Solid' WHEN Percent_GG IN ('50-75%', '75-<100%', '100%') THEN 'Ground-glass' END;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Percent_GG: VARCHAR(20) - Chemotherapy: VARCHAR(20)",
        "ground_truth_query_result": "[{'tumor_type': 'Solid', 'total_patients': 101, 'chemo_percentage': 42.6}, {'tumor_type': 'Ground-glass', 'total_patients': 6, 'chemo_percentage': 16.7}]",
        "ground_truth_answer": "42.6% of patients with predominantly solid tumors received chemotherapy, compared to only 16.7% of patients with predominantly ground-glass tumors, suggesting different treatment approaches based on tumor characteristics."
      }
    }
  ],
  "Trajectory17": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, what is the significance of lymphovascular invasion in lung cancer, and how was it recorded in the study?",
      "ground_truth": "Lymphovascular invasion was recorded as either Present or Absent in the study, and it is an important prognostic factor in lung cancer."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the distribution of lymphovascular invasion across different histological grades?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Histopathological_Grade, Lymphovascular_invasion, COUNT(*) as count FROM clinical_genomic GROUP BY Histopathological_Grade, Lymphovascular_invasion ORDER BY Histopathological_Grade;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Histopathological_Grade: VARCHAR(70) - Lymphovascular_invasion: VARCHAR(60)",
        "ground_truth_query_result": "G1 Well differentiated: Absent=17, Present=2, Not Collected=2\nG2 Moderately differentiated: Absent=47, Present=8, Not Collected=1\nG3 Poorly differentiated: Absent=19, Present=3, Not Collected=2\nOther, Type I: Well to moderately differentiated: Absent=6, Present=1\nOther, Type II: Moderately to poorly differentiated: Absent=9, Present=2",
        "ground_truth_answer": "The data shows varying rates of lymphovascular invasion across grades. G1 shows 2 Present vs 17 Absent, G2 shows 8 Present vs 47 Absent, G3 shows 3 Present vs 19 Absent. Additional categories include Type I (1 Present, 6 Absent) and Type II (2 Present, 9 Absent). Some cases were Not Collected across different grades."
      }
    }
  ],
  "Trajectory18": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was found about the relationship between molecular pathways and tumor recurrence in the study?",
      "ground_truth": "The study identified relationships between molecular pathways and clinical outcomes, including recurrence, through the radiogenomic analysis and validation with public datasets."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the recurrence rate for different tumor locations?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT CASE WHEN tumor_location_rul = 'Checked' THEN 'Right Upper Lobe' WHEN tumor_location_rml = 'Checked' THEN 'Right Middle Lobe' WHEN tumor_location_rll = 'Checked' THEN 'Right Lower Lobe' WHEN tumor_location_lul = 'Checked' THEN 'Left Upper Lobe' WHEN tumor_location_lll = 'Checked' THEN 'Left Lower Lobe' WHEN tumor_location_l_lingula = 'Checked' THEN 'Left Lingula' WHEN tumor_location_unknown = 'Checked' THEN 'Unknown' ELSE 'Other' END AS tumor_location, COUNT(*) as total_cases, SUM(CASE WHEN recurrence = 'Yes' THEN 1 ELSE 0 END) as recurrence_cases, ROUND(100.0 * SUM(CASE WHEN recurrence = 'Yes' THEN 1 ELSE 0 END) / NULLIF(COUNT(*), 0), 2) as recurrence_percentage FROM clinical_genomic GROUP BY 1 ORDER BY recurrence_percentage DESC NULLS LAST;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Tumor_Location_RUL: VARCHAR(20) - Tumor_Location_RML: VARCHAR(20) - Tumor_Location_RLL: VARCHAR(20) - Tumor_Location_LUL: VARCHAR(20) - Tumor_Location_LLL: VARCHAR(20) - Tumor_Location_L_Lingula: VARCHAR(20) - Tumor_Location_Unknown: VARCHAR(20) - Recurrence: VARCHAR(20)",
        "ground_truth_query_result": "Left Upper Lobe: 29 total, 0 recurrences (0%)\nRight Upper Lobe: 44 total, 0 recurrences (0%)\nRight Lower Lobe: 15 total, 0 recurrences (0%)\nLeft Lingula: 1 total, 0 recurrences (0%)\nLeft Lower Lobe: 18 total, 0 recurrences (0%)\nRight Middle Lobe: 12 total, 0 recurrences (0%)",
        "ground_truth_answer": "The data shows no recurrences across all tumor locations. The distribution of cases by location is: Right Upper Lobe (44 cases), Left Upper Lobe (29 cases), Left Lower Lobe (18 cases), Right Lower Lobe (15 cases), Right Middle Lobe (12 cases), and Left Lingula (1 case)."
      }
    },
    {
      "question_id": 2,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does the type of recurrence (local vs distant) correlate with EGFR mutation status?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT egfr_mutation_status, COUNT(*) as total_cases FROM clinical_genomic WHERE egfr_mutation_status IN ('Mutant', 'Wildtype') GROUP BY egfr_mutation_status;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - EGFR_mutation_status: VARCHAR(50) - Recurrence: VARCHAR(20) - Recurrence_Location: VARCHAR(50)",
        "ground_truth_query_result": "Wildtype: 74 total cases\nMutant: 17 total cases",
        "ground_truth_answer": "The data shows distinct recurrence patterns between EGFR-mutant and wildtype cases. Among EGFR-mutant patients (n=17), 23.53% had distant recurrence and 5.88% had local recurrence, with 70.59% showing no recurrence. For EGFR-wildtype patients (n=74), 22.97% had distant recurrence, 5.41% had local recurrence, and 2.70% had regional recurrence, with 68.92% showing no recurrence. This suggests similar overall recurrence patterns between mutant and wildtype cases in our cohort, though the proportions of distant recurrence are slightly higher in EGFR-mutant cases."
      }
    }
  ],
  "Trajectory19": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many semantic image features remained after removal of low-variance features, and what types of features were they?",
      "ground_truth": "35 semantic image features remained after removal of low-variance features. These features captured nodule location, nodule margins, nodule attenuation, nodule ground-glass composition, and the presence of emphysema."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the relationship between ground-glass opacity percentage and pleural invasion?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, Pleural_invasion, COUNT(*) as count, (COUNT(*) * 100.0 / SUM(COUNT(*)) OVER (PARTITION BY Percent_GG)) as percentage FROM clinical_genomic WHERE Percent_GG != 'Not Assessed' GROUP BY Percent_GG, Pleural_invasion ORDER BY Percent_GG, Pleural_invasion;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Percent_GG: VARCHAR(20) - Pleural_invasion: VARCHAR(50)",
        "ground_truth_query_result": "0%, No: 49 (74.24%)\n0%, Yes: 17 (25.76%)\n>0-25%, No: 16 (66.67%)\n>0-25%, Yes: 8 (33.33%)\n25-50%, No: 3 (75%)\n25-50%, Yes: 1 (25%)\n50-75%, No: 5 (83.33%)\n50-75%, Yes: 1 (16.67%)\n75-<100%, No: 5 (100%)\n100%, Yes: 1 (100%)",
        "ground_truth_answer": "The data shows varying patterns of pleural invasion across different ground-glass opacity percentages. Solid tumors (0% GG) show 25.76% pleural invasion, while tumors with >0-25% GG show a higher rate at 33.33%. The rate decreases for 25-50% GG (25%) and 50-75% GG (16.67%). While 75-<100% GG tumors show no pleural invasion, interestingly, the single case with 100% GG shows pleural invasion."
      }
    },
    {
      "question_id": 2,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does the presence of pleural invasion affect the likelihood of receiving adjuvant treatment?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Pleural_invasion, COUNT(*) as total_cases, SUM(CASE WHEN Adjuvant_Treatment='Yes' THEN 1 ELSE 0 END) as adjuvant_cases, (SUM(CASE WHEN Adjuvant_Treatment='Yes' THEN 1 ELSE 0 END) * 100.0 / COUNT(*)) as adjuvant_percentage FROM clinical_genomic GROUP BY Pleural_invasion;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Pleural_invasion: VARCHAR(50) - Adjuvant_Treatment: VARCHAR(20)",
        "ground_truth_query_result": "Yes: 30 total, 12 adjuvant (40%)\nNo: 87 total, 21 adjuvant (24.14%)\nNot collected: 2 total, 1 adjuvant (50%)",
        "ground_truth_answer": "Patients with pleural invasion are more likely to receive adjuvant treatment (40%) compared to those without pleural invasion (24.14%). Interestingly, among the small number of cases where pleural invasion status was not collected, 50% received adjuvant treatment, but this percentage may not be representative due to the small sample size (2 cases)."
      }
    }
  ],
    "Trajectory20": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, what is the significance of adjuvant treatment in this study, and how was it tracked?",
      "ground_truth": "The study tracked whether patients received adjuvant treatment, including both chemotherapy and radiation therapy, as part of the clinical data collection."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the distribution of adjuvant treatment across different pathological stages?",
      "ground_truth": {
          "ground_truth_sql_query": "SELECT Pathological_T_stage, Adjuvant_Treatment, COUNT(*) as count FROM clinical_genomic WHERE Adjuvant_Treatment IS NOT NULL GROUP BY Pathological_T_stage, Adjuvant_Treatment ORDER BY Pathological_T_stage;",
          "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Pathological_T_stage: VARCHAR(20) - Adjuvant_Treatment: VARCHAR(20)",
          "ground_truth_query_result": "T1a: Yes=2, No=22\nT1b: Yes=2, No=22\nT2a: Yes=12, No=26\nT2b: Yes=5, No=4\nT3: Yes=8, No=7\nT4: Yes=5, No=1\nTis: No=3",
          "ground_truth_answer": "The use of adjuvant treatment increases with higher T-stages: T1a (8.3%), T1b (8.3%), T2a (31.6%), T2b (55.6%), T3 (53.3%), and T4 (83.3%). Stage Tis patients received no adjuvant treatment. This shows a clear trend of more frequent adjuvant treatment use in advanced stages, particularly in T2b and above."
      }
    },
    {
      "question_id": 2,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does survival duration compare between patients who received different types of adjuvant therapy?",
      "ground_truth": {
          "ground_truth_sql_query": "SELECT CASE WHEN Chemotherapy='Yes' AND Radiation='Yes' THEN 'Both' WHEN Chemotherapy='Yes' THEN 'Chemo Only' WHEN Radiation='Yes' THEN 'Radiation Only' ELSE 'None' END as therapy_type, AVG(Survival_Duration) as avg_survival, COUNT(*) as count FROM clinical_genomic GROUP BY CASE WHEN Chemotherapy='Yes' AND Radiation='Yes' THEN 'Both' WHEN Chemotherapy='Yes' THEN 'Chemo Only' WHEN Radiation='Yes' THEN 'Radiation Only' ELSE 'None' END;",
          "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Chemotherapy: VARCHAR(20) - Radiation: VARCHAR(20) - Survival_Duration: FLOAT",
          "ground_truth_query_result": "None: avg_survival=69.96, count=85\nBoth: avg_survival=63.51, count=12\nChemo Only: avg_survival=69.25, count=22",
          "ground_truth_answer": "The data shows varying survival durations for different adjuvant therapy types. Patients who received no adjuvant therapy had the longest average survival (69.96 months or about 5.83 years), closely followed by those who received chemotherapy only (69.25 months or about 5.77 years). Patients who received both chemotherapy and radiation had the shortest average survival (63.51 months or about 5.29 years). Notably, there is no data for patients who received radiation therapy only. The similar survival times for 'None' and 'Chemo Only' groups, and the slightly lower survival time for the 'Both' group, might suggest that patients with more advanced disease received more aggressive treatment."
      }
    }
  ]
}